Information Provided By:
Fly News Breaks for August 3, 2016
DXCM
Aug 3, 2016 | 08:17 EDT
Leerink analyst Danielle Antalffy raised her price target for Dexcom to $115 from $90 as the company's continuous glucose monitoring, or CGM, adoption momentum continues, with sales up 47% in the quarter despite increasingly tough year over year comparables. This growth level remains above the company's previously-stated sustainable top-line growth goal of 35%-40%, the analyst tells investors in a research note. Antalffy reiterates an Outperform rating on the shares.